AstraZeneca PLC Announces Q1 2016 Results

29 April 2016

Financial Summary

$m % change
CER1 Actual
Total Revenue2 6,115 5 1
Core3 Op. Profit 1,593 (8) (12)
Core EPS $0.95 (7) (12)
Reported Op. Profit 1,038 17 11
Reported EPS $0.51 26 17

  • Total Revenue grew by 5%, driven by a significant increase in Externalisation Revenue

  • Core R&D costs increased by 15%, reflecting recent acquisitions; Core R&D costs declined versus Q4 2015

  • Core SG&A costs fell by 6% and represented 35% of Total Revenue (Q1 2015: 39%)

  • Core EPS declined by 7%, reflecting a significant reduction in Other Operating Income

  • Reported Operating Profit grew by 17% to $1,038m. Reported EPS grew by 26% to $0.51

  • FY 2016 CER guidance unchanged

Commercial Highlights

The Growth Platforms grew by 6%, representing 56% of Total Revenue:

1. Respiratory: +2%. Growth of Pulmicort and newly-acquired medicines offset by a decline in sales of Symbicort

2. Brilinta/Brilique: +46%. Continued encouraging progress; post-MI approval in the EU

3. Diabetes: +23%. Strong sales growth included an increase of +65% in Emerging Markets.

Global Farxiga/Forxiga growth of 128%

4. Emerging Markets: +6%. Good China sales growth of +11%; slowdowns in other regions

5. Japan: -7%, reflecting destocking ahead of mandated biennial price reductions from April 2016

6. New Oncology: Contributed $99m. Launch of Tagrisso in key markets progressing well

Click on, or paste the following link into your web browser, to view the associated PDF document.

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit:


Documents & Links